Gut Microbiome-Derived Metabolites in Alpha-Synuclein Propagation

🧫 Experiment Protocol ClinicalParkinson's DiseaseIDhumanproposed

# Gut Microbiome-Derived Metabolites in Alpha-Synuclein Propagation ## Background and Rationale This translational clinical study investigates the role of gut microbiome-derived metabolites in alpha-synuclein aggregation and propagation, addressing a critical knowledge gap in Parkinson's disease (PD) pathogenesis. Growing evidence supports the gut-brain axis hypothesis in neurodegeneration, where altered intestinal microbiota may contribute to alpha-synuclein misfolding and subsequent neuronal death. The study employs a comprehensive multi-modal approach combining clinical assessments, advanced metabolomics, and mechanistic cellular assays to establish causal relationships between specific microbial metabolites and alpha-synuclein pathology. The primary design involves a case-control study with longitudinal follow-up, recruiting 120 PD patients and 80 age-matched healthy controls. Participants undergo detailed clinical phenotyping using Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS), alongside collection of fecal samples for 16S rRNA sequencing and untargeted metabolomics analysis. Key measurements include quantification of short-chain fatty acids, tryptophan metabolites, bile acids, and other bioactive compounds previously implicated in neuroinflammation. Patient-derived peripheral blood mononuclear cells and induced pluripotent stem cell-derived neurons will be exposed to identified metabolites to assess alpha-synuclein aggregation kinetics using thioflavin-T fluorescence and transmission electron microscopy. The innovation lies in directly linking human gut metabolome profiles with cellular alpha-synuclein propagation assays, providing mechanistic insights into microbiome-mediated neurodegeneration. This research could identify novel therapeutic targets for disease-modifying interventions and biomarkers for early PD detection, potentially revolutionizing treatment approaches by targeting the gut-brain axis rather than solely focusing on brain pathology. This experiment directly tests predictions arising from the following hypotheses: - **Microbial Metabolite-Mediated α-Synuclein Disaggregation** - **Gut Barrier Permeability-α-Synuclein Axis Modulation** - **Enteric Nervous System Prion-Like Propagation Blockade** - **Vagal Afferent Microbial Signal Modulation** - **Microbiome-Derived Tryptophan Metabolite Neuroprotection** ## Experimental Protocol Phase 1 (Months 1-6): Recruit 120 PD patients (Hoehn-Yahr stages I-III) and 80 healthy controls from movement disorder clinics. Obtain informed consent and perform baseline clinical assessments including MDS-UPDRS, Montreal Cognitive Assessment, and constipation scoring. Collect fecal samples (10g) in sterile containers, flash-freeze at -80°C within 2 hours. Phase 2 (Months 7-12): Extract microbial DNA using QIAamp PowerFecal Pro DNA Kit, perform 16S rRNA V4 region sequencing on Illumina MiSeq platform. Conduct untargeted metabolomics using LC-MS/MS with HILIC and reverse-phase chromatography. Target analysis of 150+ metabolites including SCFAs, indoles, phenolics, and bile acids. Phase 3 (Months 13-20): Isolate PBMCs from 50ml blood samples using Ficoll density gradient centrifugation. Culture primary neurons differentiated from patient iPSCs (n=20 per group) for 21 days. Treat cells with identified metabolites at physiologically relevant concentrations (1-100μM) for 72 hours. Phase 4 (Months 21-26): Measure alpha-synuclein aggregation using thioflavin-T kinetic assays, immunofluorescence with Syn-1 antibodies, and transmission electron microscopy. Quantify cell viability using MTT assays and assess neuroinflammatory markers (IL-1β, TNF-α) via ELISA. Phase 5 (Months 27-28): Perform statistical analysis using random forest algorithms and correlation networks to identify metabolite signatures predictive of alpha-synuclein pathology. ## Expected Outcomes - 1. Significant differences in gut microbiome composition between PD patients and controls, with 15-20% reduction in beneficial bacteria (Lachnospiraceae, Ruminococcaceae) and 25-30% increase in potentially harmful species (Enterobacteriaceae). - 2. Identification of 8-12 discriminatory metabolites with area under ROC curve >0.75 for distinguishing PD patients, including reduced butyrate levels (40-50% decrease) and elevated phenolic compounds (2-3 fold increase). - 3. Dose-dependent acceleration of alpha-synuclein aggregation kinetics in neuronal cultures exposed to PD-associated metabolites, with 30-50% faster fibril formation (p<0.001) compared to control conditions. - 4. Strong correlation (r>0.6, p<0.01) between specific metabolite concentrations and MDS-UPDRS motor scores, particularly for tryptophan pathway metabolites and motor severity. - 5. Reduced neuronal viability (20-35% decrease) and increased inflammatory cytokine release (2-4 fold elevation) in cultures treated with PD-derived metabolite profiles versus healthy control profiles. - 6. Development of a predictive metabolomic signature achieving 80-85% accuracy for PD classification, with cross-validation sensitivity >75% and specificity >80%. ## Success Criteria - • Successful recruitment and retention of >90% of target sample size (200 total participants) with complete clinical and biospecimen data collection - • Identification of at least 5 metabolites showing statistically significant differences (p<0.01, FDR-corrected) between PD patients and healthy controls - • Demonstration of significant correlation (p<0.05) between at least 3 identified metabolites and alpha-synuclein aggregation rates in cellular assays - • Achievement of metabolomic classifier performance with AUC >0.75 for PD diagnosis and correlation coefficient >0.5 with clinical severity scores - • Successful validation of findings in independent subset (20% holdout) with maintained statistical significance and effect sizes >50% of discovery cohort - • Generation of at least 2 high-impact publications and 1 provisional patent application for identified biomarkers or therapeutic targets

Source: wiki

🧫 Experiment Extras

🟢 Parkinson's Disease 🧠 Neurodegeneration

📊 Evidence Profile

0 supporting 0 contradicting 0 neutral

🌍 Provenance Graph 1 nodes, 0 edges

No provenance edges found